CDC-RFA-PS22-2209: Transgender Status-Neutral Community-to-Clinic Models to End the HIV Epidemic
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2021.
Centers for Disease Control - NCHHSTP offered grants to any type of organization. It expected to make about 4 awards worth $8.0 million in total. Applications closed on March 5, 2022.
From the official notice on Grants.gov, last changed March 4, 2022. Checked November 7, 2026.
- Total funding$8.0 million
- Expected awards4
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | December 22, 2021 |
|---|---|
| Deadline | March 5, 2022 |
| Archived by Grants.gov | April 4, 2022 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
The applicant must have a history of providing clinical services to transgender persons, including gender affirming hormone therapy, or must have a history of working with an organization that provides clinical services to transgender persons, including gender affirming hormone therapy. For applicants that are TG clinics, a history of providing clinical services to TG persons, including gender affirming hormone therapy, should be described in the application narrative. For applicants that are not TG clinics, a letter from the partnering TG clinic indicating their support of the application, description of current TG-specific clinic services offered, and plans to implement proposed activities is required
Is this a realistic fit?
- Most of the program's money (93% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
TG persons, especially transgender women (TGW), have a high prevalence of HIV and lifetime risk of acquiring HIV. In 2019, 625 TGW and 45 transgender men (TGM) were diagnosed with HIV in the United States and 6 dependent areas.1 About half (51%) of these diagnoses were in persons aged 20-29 years. In the 2019-2020 National HIV Behavioral Surveillance Trans cycle, 42% of TGW tested positive for HIV.2 Racial/ethnic disparities in positivity were also found, with positivity rates of 62% among Black/African American (Black) TGW and 35% among Hispanic/Latina (Hispanic) TGW compared to 17% among White TGW.Despite the disproportionate burden of HIV among TGW, receipt of HIV prevention and care services have been suboptimal. Among TG persons, 92% reported that they were aware of PrEP but only 32% that they have used it.2 In 2019, viral suppression among persons with diagnosed HIV was 67% among TGW.3 Large proportions of TG persons were living at or below the poverty level, experienced homelessness, or exchanged sex for money or drugs.2 Large proportions of TGW also reported verbal or physical abuse, including by a sexual partner, and suicidal ideation and behavior.2 Substance use is prevalent in TG populations.4 All of these factors have an impact on access to and utilization of HIV prevention and care services. In addition, some clinical staff might lack TG cultural awareness, and this can be a barrier to TG persons remaining engaged in health care. Feminizing or masculinizing gender-affirming hormone therapy was reported by 72% of TGW, with an additional 20% wanting to take hormones.2 Many TG persons seek hormone therapy at TG clinics that serve as centers of excellence for TG health and well-being. These encounters provide opportunities for HIV education and counseling, HIV testing and risk assessment, status-neutral HIV services, sexually transmitted infection (STI) testing, and other health care services. HIV testing identifies HIV-negative persons who should be assessed for preexposure prophylaxis (PrEP) and nonoccupational postexposure prophylaxis (nPEP) indications,5,6 and if indicated, offered and prescribed PrEP or nPEP. Patients who seek care in TG clinics for gender-affirming services such as hormone therapy can be assessed for PrEP indications and offered PrEP. HIV testing can also identify persons with HIV for rapid antiretroviral therapy (ART) initiation.
Who has won Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance grants before
From fiscal 2021 to 2025, Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (93.944) awarded $122 million across 81 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| City of New York | New York | 3 | $8.8 million |
| County of Los Angeles | California | 3 | $6.7 million |
| California Department of Public Health | California | 4 | $6.6 million |
| City of Houston | Texas | 4 | $6.2 million |
| New Jersey Department of Health | New Jersey | 3 | $6.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS22-2209 still open?
No. It closed on March 5, 2022.
Who can apply for Transgender Status-Neutral Community-to-Clinic Models to End the HIV Epidemic?
Centers for Disease Control - NCHHSTP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Transgender Status-Neutral Community-to-Clinic Models to End the HIV Epidemic?
Closed March 5, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $8.0 million in total across about 4 awards.
Who has won Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance grants before?
The largest recipients over five fiscal years were City of New York, County of Los Angeles, California Department of Public Health. The program made 81 awards worth $122 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)